dc.date.accessioned |
2021-06-08T09:11:19Z |
|
dc.date.available |
2021-06-08T09:11:19Z |
|
dc.date.issued |
2020 |
|
dc.identifier.issn |
1076-6294 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/95848 |
|
dc.description |
This research was funded by Sakarya University Scientific Research Projects Unit (Project Number: 2016-40-02-004). |
|
dc.description |
Bu yayının lisans anlaşması koşulları tam metin açık erişimine izin vermemektedir. |
|
dc.description.abstract |
This study aimed at investigating the in vitro effectiveness of aztreonam/avibactam, colistin/avibactam, colistin/apramycin, and meropenem/apramycin combinations against carbapenemase-producing, extensively drug-resistant (XDR) Klebsiella pneumoniae strains. This study evaluated 38 carbapenem-resistant, carbapenemase-producing, and XDR K. pneumoniae strains. The checkerboard method was used to examine the efficacy of aztreonam/avibactam, and meropenem/apramycin combinations in all strains and the colistin/apramycin combination in colistin-resistant strains (n = 26). It was found that when used alone, aztreonam and avibactam had high minimum inhibitory concentration values in all strains and that all strains were resistant to aztreonam. Nevertheless, the aztreonam/avibactam combination was found to have a synergistic effect against all strains. Apramycin alone was effective against 30 K. pneumoniae strains (79%); however, 8 strains (21%) were found to be resistant. In the synergy testing of 26 colistin-resistant strains with the checkerboard method, the colistin/apramycin combination was found to have a synergistic effect against 4 strains (15.3%), an antagonistic effect against 8 strains (30.7%), and an additive effect against 14 strains (54%). By comparison, the meropenem/apramycin combination had a synergistic effect against 20 strains (52%) and an additive effect against 12 strains (31%). The aztreonam/avibactam combination showed a high in vitro synergistic effect on carbapenemase-producing and XDR K. pneumoniae strains, such as Metallo-beta-lactamase, and provided good prospects for the successful treatment. The meropenem/apramycin combination was also highly synergistic. The synergistic effects were low for the colistin/apramycin combination that was tested on colistin-resistant strains. However, it is promising that apramycin has low minimal inhibitory concentration values. |
|
dc.description.sponsorship |
Sakarya University Scientific Research Projects UnitSakarya University [2016-40-02-004] |
|
dc.language |
English |
|
dc.language.iso |
eng |
|
dc.publisher |
MARY ANN LIEBERT, INC |
|
dc.relation.isversionof |
10.1089/mdr.2019.0498 |
|
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.subject |
CEFTAZIDIME-AVIBACTAM ACTIVITY |
|
dc.subject |
ENTEROBACTERIACEAE |
|
dc.subject |
THERAPY |
|
dc.subject |
COLISTIN |
|
dc.title |
Investigation of the In Vitro Effectiveness of Aztreonam/Avibactam, Colistin/Apramycin, and Meropenem/Apramycin Combinations Against Carbapenemase-Producing, Extensively Drug-Resistant Klebsiella pneumoniae Strains |
|
dc.type |
Article |
|
dc.contributor.authorID |
Altindis, Mustafa/0000-0003-0411-9669 |
|
dc.identifier.volume |
26 |
|
dc.identifier.startpage |
1291 |
|
dc.identifier.endpage |
1297 |
|
dc.relation.journal |
MICROBIAL DRUG RESISTANCE |
|
dc.identifier.issue |
11 |
|
dc.identifier.doi |
10.1089/mdr.2019.0498 |
|
dc.identifier.eissn |
1931-8448 |
|
dc.contributor.author |
Kilic, Umit |
|
dc.contributor.author |
Koroglu, Mehmet |
|
dc.contributor.author |
Olmez, Mehmet |
|
dc.contributor.author |
Altindis, Mustafa |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|
dc.identifier.pmıd |
32401692 |
|